Overactive bladder is a common medical condition where there is sudden urge of urination. Overactive bladder is sometimes coupled with urine leakage, condition known as incontinence. Millions of people across the globe suffers from overactive bladder and it is more common in old age people.
Urine leakage and frequent urination are the main symptoms of overactive bladder. The frequency of urination in the patient is around eight times a day. Moreover, frequent urination during sleep hours is common in such patients. Overactive bladder is commonly diagnosed by tests such as urine culture, bladder scan, cystoscopy or urodynamic testing.
Robust drug pipeline with drugs in phase II and phase III clinical trials, soon expected to be in the market, are expected to drive the overactive bladder treatment market growth. However, alternate therapies such as the neuromodulation therapy which includes sacral neuromodulation and percutaneous tibial nerve stimulation to deliver electric impulse to nerve, are expected to hinder the overactive bladder treatment market growth.
Overactive Bladder Treatment Market Dynamics
High prevalence of overactive bladder is expected to propel the overactive bladder treatment market growth over the forecast period. Moreover, increasing awareness about the importance of diagnosis and treatment of the disease is a key factor leading to increase in number of patients treated for overactive bladder.
Furthermore, increasing number of drug development programs for overactive bladder is expected to fuel the overactive bladder treatment market growth, by adding new drug in the market. Currently, generic drugs such as cholinergic receptor inhibitors are available for treatment of the condition. Therefore, development and approval of new drug entity with better drug profile is expected to boost the market growth.
For instance, in 2018, Urovant Sciences—a biopharmaceutical company that focuses on developing novel therapy for urologic conditions—entered in phase III clinical trial for its drug —Vibegron —an oral Beta-andrenergic agonist for indication of overactive bladder treatment.
Furthermore, Taris Biomedical LLC—entered phase II clinical trials for its drug candidate TAR-302 for the treatment of overactive bladder. TAR 302 is a trospium chloride-based continuous local therapy, which is expected to efficiently aid in treatment of overactive bladder with few side effects.
Key players operating in the market are focused on development of combinational therapies. For instance, in 2017, Astellas Pharma, Inc. received supplemental New Drug Application (sNDA) from FDA for conditional therapy of mirabegron and solifenacin succinate for the treatment of urinary incontinence.
Overactive Bladder Treatment Market - Regional Analysis
The global overactive bladder treatment market is segmented into six regions that include, North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America overactive bladder treatment market holds dominant position amongst other regions, owing to high prevalence of overactive bladder in the region. For instance, according to the journal Current Bladder Dysfunction Reports, 2016 review, millions of people suffer from overactive bladder in the U.S. and estimates continuous increase in cost of overactive bladder management. However, increasing awareness about the disease in Asia Pacific regions is expected to boost the regional Asia Pacific overactive bladder treatment market growth in the region, over the forecast period at a fast rate.
Overactive Bladder Treatment Market – Competitive Analysis
Key players operating in the overactive bladder treatment market include, Janssen Pharmaceuticals Inc., Accord Healthcare Inc., Mylan Pharmaceuticals Inc., Barr Laboratories Inc. (subsidiary of Teva Pharmaceuticals), Alembic Pharmaceuticals Ltd., Pfizer Inc., Astellas Pharma Inc., Endo International PLC, and Invagen Pharmaceuticals Inc.
Key players operating in the market are focusing on leveraging their expertise to develop novel treatment therapies for the disease, to enhance their market share. For instance, in 2017, UroGen Pharma Ltd .a clinical-stage biopharmaceutical company in collaboration with Allergan Pharmaceuticals International Limited entered in phase II clinical trial for RTGel in combination with BOTOX, for overactive bladder treatment. RTGel is a hydrogel-based proprietary formulation of UroGen Pharma Ltd.
Overactive Bladder Treatment Market - Taxonomy
On the basis of drug type, the overactive bladder treatment market is segmented into:
On the basis of route of administration, the overactive bladder treatment market is segmented into:
On the basis of distribution channel, the overactive bladder treatment market is segmented into:
On the basis of region, the overactive bladder treatment market is segmented into:
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.[email protected]
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.